Different effects of nabilone and cannabidiol on binocular depth inversion in Man.
F M Leweke, Udo Schneider, M Radwan, E Schmidt, Hinderk M. Emrich
Pharmacology, Biochemistry, and Behavior May 2000 DOI: 10.1016/s0091-3057(00)00201-x (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Sample size | 9 |
| Population | Healthy male volunteers |
| Interventions | Nabilone Cannabidiol |
| Measures | Binocular depth inversion |
| Topics | CBD |
| Key findings | Nabilone significantly impaired binocular depth inversion, while combined application with cannabidiol somewhat reduced this effect, suggesting a modulatory role of cannabidiol on nabilone-induced perceptual changes. |
Abstract
The physiological and pathophysiological roles of the central nervous endogenous cannabinoid system are not completely understood, but still represent a challenge in basic neurobiological, cognitive, and psychiatric research. The system has been implicated in the pathogenesis of schizophrenia. Binocular depth inversion, an illusion of visual perception, provides a model of impaired perception during psychotic states. Using this model the effects of nabilone, a psychoactive synthetic 9-trans-ketocannabinoid, and of cannabidiol, the main natural component of herbal cannabis, and a combined application of both substances on binocular depth inversion and behavioural states were investigated in nine healthy male volunteers. The time course of the effects of both substances on binocular depth inversion was analysed after oral administration using three different groups of natural stimuli. A significant impairment of binocular depth perception was found when nabilone was administered, but combined application with cannabidiol revealed somewhat reduced effects on binocular depth inversion. The influence of psychoactive cannabinoids on this perceptual model and the role of the endogenous cannabinoid system in visual information processing are discussed.
Comparable studies
Other randomized controlled trials on CBD, most cited first.
Citations in the library
Cited by 42
- High-potency cannabis and the risk of psychosis The British Journal of Psychiatry November 30, 2009
- Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment Journal of Psychopharmacology October 5, 2012
- Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug Brazilian Journal of Medical and Biological Research April 1, 2006
- Traditional marijuana, high‐potency cannabis and synthetic cannabinoids: increasing risk for psychosis World Psychiatry September 22, 2016
- Gone to Pot – A Review of the Association between Cannabis and Psychosis Frontiers in Psychiatry May 22, 2014
and 37 more in the library
Cites 6
- Elevated endogenous cannabinoids in schizophrenia. Neuroreport June 3, 1999
- Effects of synthetic delta9-tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in man. Psychopharmacology March 1999
- Reduced binocular depth inversion as an indicator of cannabis-induced censorship impairment. Pharmacology, Biochemistry, and Behavior November 1991
- Cannabinoid receptor localization in brain. Proceedings of the National Academy of Sciences March 1990
- Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 1982
and 1 more in the library